Muscarinic Approaches in Schizophrenia: New Directions in Treatment to Address Unmet Needs

The treatment landscape for schizophrenia is expanding beyond traditional dopamine D2 receptor blockade, with muscarinic receptor-targeting therapies offering novel approaches to symptom management. This session will review the limitations of conventional antipsychotics, the science behind muscarinic receptor modulation, and the latest clinical data on available and emerging agents. Through expert insights and practical case-based discussion, participants will gain strategies for patient selection, treatment initiation, adverse effect management, and patient-centered communication to support the integration of these therapies into clinical practice.

Supported by an educational grant from Bristol-Myers Squibb.